Core Insights - The AI-native hospital Tianhe program aims to transform healthcare delivery by shifting from a "service finds people" model to a "people find service" model, enhancing proactive collaboration in medical care [1] - The program has been implemented in Tianjin's Haihe Hospital and is expanding to other hospitals in the Beijing-Tianjin-Hebei region, promoting intelligent transformation in medical practices [1] Group 1: AI Integration in Clinical Settings - The AI system assists doctors by automatically retrieving patient data and generating structured medical records, significantly reducing the time spent on data retrieval by at least 5 minutes per patient [2][3] - The AI system utilizes natural language processing to understand clinical intentions and integrates various data sources, effectively addressing the challenge of fragmented medical data [3] - The implementation of AI has led to an increase in daily patient consultations and improved completeness of medical records within three months [3] Group 2: Risk Monitoring and Management - The AI system acts as a "risk observer," providing real-time alerts for patient conditions, allowing for proactive risk management rather than reactive responses [5][6] - The system can perform real-time risk assessments for up to 1,000 hospital beds, conducting evaluations three times a day across more than 20 indicators, which was previously challenging [7] - The integration of various data sources enables the system to automatically generate intervention suggestions based on real-time patient data, enhancing patient safety [6] Group 3: Out-of-Hospital Monitoring - The AI system extends its monitoring capabilities beyond hospital walls, allowing for continuous patient management through wearable devices and home monitoring tools [8] - Nearly 10,000 high-risk chronic disease patients are now under this "boundary-less" management model, resulting in a 20% reduction in readmission rates compared to the previous year [8] - The ultimate goal of the AI-native hospital system is to integrate intelligent solutions throughout the healthcare process, ensuring accessible quality services for all [8]

Core Insights - The integration of AI in the healthcare sector is accelerating, addressing issues such as inefficiency, misdiagnosis, and uneven distribution of medical resources [1][7][11]. Industry Overview - AI is increasingly penetrating various aspects of life, including healthcare, where it shows potential in disease diagnosis, treatment planning, surgical assistance, and resource management [1]. - The AI+ healthcare sector is entering a rapid development phase, supported by national policies and investment interest [7][11]. Company Highlights - Shenzhen Ruixin Intelligent Medical Technology Co., Ltd. has developed an AI-driven fully automated vascular interventional surgical robot, which allows remote operation through voice commands [3][4]. - The company was founded in 2017 by three PhD graduates from renowned U.S. universities and has completed five rounds of financing, attracting investments from notable firms like Guotou Innovation and Tencent [3][4]. Product Development - The AI surgical robot aims to enhance precision, efficiency, and safety in cardiovascular surgeries, allowing for a collaborative approach between doctors and AI systems [4][5]. - The device has completed prototype production and experimental trials, with plans for animal surgeries in the latter half of the year and a target market launch in 2027 [5]. Market Potential - The AI+ healthcare market in China reached 31.5 billion yuan in 2023, with projections to exceed 80 billion yuan by 2025, reflecting a compound annual growth rate of 58.3% [11]. - Investment firms are increasingly focusing on this sector, with Guotou Innovation having invested in nearly 70 companies, amounting to approximately 15 billion yuan [8]. Challenges and Recommendations - Despite the promising outlook, challenges such as data privacy, AI diagnostic reliability, and regulatory issues persist [11][12]. - Recommendations include employing advanced encryption for data protection, providing AI training for medical professionals, and establishing ethical guidelines for AI in healthcare [12].

Core Viewpoint - The integration of AI in the healthcare sector is accelerating, providing innovative solutions to address inefficiencies, misdiagnosis, and uneven distribution of medical resources [1][6]. Group 1: AI in Healthcare - AI is penetrating various aspects of life, including healthcare, where it enhances disease diagnosis, treatment planning, surgical assistance, and resource management [1]. - The AI-driven automatic vascular intervention surgical robot developed by Shenzhen Ruixin Intelligent Medical Technology Co., Ltd. showcases the potential of AI in performing complex medical procedures [3][4]. - The AI surgical robot aims to improve the precision, efficiency, and safety of cardiovascular surgeries, allowing doctors to operate in less hazardous environments [3][4]. Group 2: Market Trends and Projections - The AI+ healthcare market in China reached 31.5 billion yuan in 2023 and is expected to exceed 80 billion yuan by 2025, with a compound annual growth rate of 58.3% [11]. - The Chinese government is supporting the AI+ healthcare sector through policies and guidelines, which are expected to further stimulate growth [7][8]. Group 3: Challenges and Solutions - Despite the promising outlook, challenges such as data privacy, AI diagnostic reliability, and regulatory issues remain prevalent in the healthcare sector [12]. - Companies are focusing on close communication with clinical experts to ensure that AI products meet clinical needs, while also reducing costs significantly compared to existing products [12]. - Recommendations for overcoming challenges include implementing advanced encryption for data protection, providing AI training for medical professionals, and establishing ethical guidelines for AI use in healthcare [12].

Core Viewpoint - The stock of Sairis Medical Technology Group Co., Ltd. has experienced an abnormal trading fluctuation, with a cumulative closing price increase of over 20% in three consecutive trading days, prompting the company to issue a notice regarding this situation [2][3]. Group 1: Stock Trading Abnormality - The company's stock price has deviated significantly, with a cumulative increase of over 20% in three consecutive trading days, which is classified as an abnormal trading fluctuation according to the Shanghai Stock Exchange rules [2][3]. - The company has conducted a self-examination and confirmed that its production and operational activities are normal, with no significant changes in the market environment or industry policies [4]. Group 2: Verification of Major Events - The company has verified with its controlling shareholder, Saihai (Shanghai) Health Technology Co., Ltd., and its actual controller, Mr. Wen Wei, that there are no undisclosed major events that could affect the stock price, including major asset restructuring, share issuance, or significant business cooperation [4]. - There have been no significant media reports or market rumors that could impact the company's stock price, and no other sensitive information has been identified that could affect the stock [5][6]. Group 3: Board of Directors' Statement - The board of directors confirms that there are no undisclosed matters that should be reported according to the Shanghai Stock Exchange rules, and all previously disclosed information is accurate without the need for correction or supplementation [10].

上海联影医疗科技股份有限公司董事会薪酬与考核委员会 （1）最近 12 个月内被证券交易所认定为不适当人选； （2）最近 12 个月内被中国证监会及其派出机构认定为不适当人选； （3）最近 12 个月内因重大违法违规行为被中国证监会及其派出机构行政 处罚或者采取市场禁入措施； 关于公司 2025 年限制性股票激励计划 （4）具有《公司法》规定的不得担任公司董事、高级管理人员情形的； （5）法律法规规定不得参与上市公司股权激励的； （6）中国证监会认定的其他情形。 首次授予激励对象名单（首次授予日）的核查意见 上海联影医疗科技股份有限公司（以下简称"公司"）于 2025 年 8 月 25 日 召开第二届董事会 2025 年第三次会议，审议通过了《关于向公司 2025 年限制 性股票激励计划激励对象首次授予限制性股票的议案》。 公司董事会薪酬与考核委员会依据《中华人民共和国公司法》（以下简称 "《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公 司股权激励管理办法》（以下简称"《管理办法》"）、《上海证券交易所科创板股 票上市规则》（以下简称"《上市规则》"）、《科创板上市公司自律监管指南 ...

Group 1 - The board of directors of Shanghai RunDa Medical Technology Co., Ltd. held its 24th meeting on August 26, 2025, with all 11 directors present, including independent directors attending via communication [1] - The meeting approved the 2025 semi-annual report and its summary, with a unanimous vote of 11 in favor [2] - A special report on the storage and actual use of raised funds for the first half of 2025 was also approved, reflecting accurate management of the funds [3] Group 2 - The board approved an increase in the estimated amount for daily related party transactions for 2025 due to business development needs, with 9 votes in favor and 2 abstentions [4] - The board decided to cancel the supervisory board and revise the company's articles of association and related systems, transferring the supervisory powers to the audit committee [5] - The board proposed to reappoint Zhonghua Accounting Firm as the financial audit and internal control audit institution for 2025, with unanimous approval [5] - A resolution to convene the first extraordinary general meeting of shareholders in 2025 was also passed, with all directors voting in favor [6]

南京麦澜德医疗科技股份有限公司2025 年半年度报告摘要 公司代码：688273 公司简称：麦澜德 南京麦澜德医疗科技股份有限公司 南京麦澜德医疗科技股份有限公司2025 年半年度报告摘要 第一节 重要提示 规划，投资者应当到上海证券交易所网站（http://www.sse.com.cn/）网站仔细阅读半年度报告 全文。 第二节 公司基本情况 公司股票简况 公司股票简况 | 股票种类 股票上市交易所 | | 股票简称 | 股票代码 | 变更前股票简称 | | | --- | --- | --- | --- | --- | --- | | A股 上海证券交易所科创板 | | 麦澜德 | 688273 无 | | | | 公司存托凭证简况 | | | | | | | □适用 √不适用 | | | | | | | 联系人和联系方式 | | | | | | | 联系人和联系方式 | 董事会秘书（信息披露境内代表） | | | 证券事务代表 | | | 姓名 陈江宁 | | 倪清清 | | | | | 025-69782957 电话 | | 025-69782957 | | | | | 办公地址 | 南京市雨花台区凤展 ...

证券代码：688273 证券简称：麦澜德 公告编号：2025-030 南京麦澜德医疗科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 南京麦澜德医疗科技股份有限公司（以下简称"公司"）于 2025 年 8 月 15 日以 邮件方式发出第二届董事会第十五次会议通知（以下简称"本次会议"），本次会议 于 2025 年 8 月 25 日以现场及通讯方式召开，由董事长杨瑞嘉先生召集并主持， 本次会议应到董事 8 人，实到董事 8 人。本次会议的召集召开符合《中华人民共 和国公司法》（以下简称"《公司法》"）、《上海证券交易所科创板股票上市 规则》等相关法律法规、规范性文件及《南京麦澜德医疗科技股份有限公司章程》 （以下简称"《公司章程》"）的有关规定，作出的决议合法、有效。 报告>的议案》 董事会认为：公司 2025 年半年度募集资金存放和实际使用情况符合《上海证 券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引 第 1 号——规范运作》《上市公司募集资金监管规则》等相 ...

Meeting Overview - The second meeting of the supervisory board of Nanjing Mailland Medical Technology Co., Ltd. was held on August 25, 2025, with all three supervisors present, confirming compliance with relevant laws and regulations [1] Financial Report Approval - The supervisory board approved the 2025 semi-annual report, affirming that the report's preparation and review processes adhered to legal requirements and accurately reflected the company's financial status and operational results [1] - The board ensured that there were no violations of confidentiality during the report's preparation [1] Fund Management Report - The board approved the special report on the storage and use of raised funds, confirming compliance with relevant regulations and that the actual use of funds matched previously disclosed information [2] Auditor Appointment - The board approved the reappointment of Zhongxinghua Accounting Firm, confirming its qualifications and ability to meet the company's auditing needs for the 2025 fiscal year [3] Related Party Transactions - The board approved an increase in the estimated amount for daily related party transactions for 2025, stating that it aligns with the company's operational needs and does not harm shareholder interests [4] Fund Replacement Proposal - The board approved a proposal to use self-raised funds for project payments, which will later be replaced with raised funds, enhancing operational efficiency without altering the intended use of raised funds [5] Governance Changes - The board approved the cancellation of the supervisory board and amendments to the company’s articles of association, aiming to improve governance in line with legal requirements [6]

Meeting Information - The company will hold a temporary shareholders' meeting on September 12, 2025, at 1:30 PM [5] - The meeting will take place at the Star Center, 8th Floor, 89 Zhapu Road, Hongkou District, Shanghai [5][8] - Voting will be conducted through both on-site and online methods using the Shanghai Stock Exchange's network voting system [5][4] Voting Procedures - Shareholders can vote via the trading system or the internet voting platform, with specific time slots for each method [4][5] - Shareholders holding multiple accounts can aggregate their voting rights across all accounts [7] - The first voting result will be considered valid if the same voting right is exercised multiple times [7] Attendance and Registration - Only shareholders registered by the close of trading on the equity registration date are eligible to attend the meeting [7] - Registration for attendance must be completed in person, with specific documentation required for both individual and corporate shareholders [7][10] - The registration period is set for September 10, 2025, from 9:30 AM to 11:30 AM and 1:30 PM to 4:00 PM [11] Proxy Voting - Shareholders can appoint a proxy to attend the meeting and vote on their behalf, with specific documentation required for the proxy [7][9] - The proxy must present identification and authorization documents to register for the meeting [7][10]